RBC Capital Sticks to Its Buy Rating for Allscripts (MDRX)

In a report issued on August 4, Sean Dodge from RBC Capital maintained a Buy rating on Allscripts (MDRXResearch Report), with a price target of $22.00. The company’s shares closed last Friday at $17.53.

According to, Dodge is a 1-star analyst with an average return of -1.3% and a 46.2% success rate. Dodge covers the Technology sector, focusing on stocks such as NextGen Healthcare, Thorne HealthTech, and GoodRx Holdings.

Currently, the analyst consensus on Allscripts is a Hold with an average price target of $19.50, a 20.0% upside from current levels. In a report issued on July 25, SVB Securities also maintained a Buy rating on the stock.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $23.25 and a one-year low of $13.05. Currently, Allscripts has an average volume of 1.61M.

Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MDRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allscripts Healthcare Solutions, Inc. engages in the provision of clinical, financial, connectivity, information solutions, and related professional services. It operates through the following segments: Clinical and Financial Solutions; Population Health; and Netsmart. The Clinical and Financial Solutions segment involves in the sale of clinical software applications and financial and information solutions. The Population Health segment offers health management and coordinated care solutions. The Netsmart segment operates in the home care and behavioral healthcare information technology field throughout the United States. The company was founded in 1986 and is headquartered in Chicago, IL.

Read More on MDRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed